The study cannot separate a true drug effect from other differences between cannabis users and non-users, and it did not evaluate mood or safety outcomes.What did the study actually measure?It measured performance on a timing precision task and an attention and inhibitory-control task, comparing chronic cannabis users and non-users with bipolar disorder to healthy adults, plus a separate acute THC-versus-placebo trial.What is the self-medication hypothesis mentioned in the study?It is the idea that people with bipolar disorder may use cannabis to relieve cognitive symptoms like poor concentration or a distorted sense of time, which the study's pattern of results is consistent with but does not prove.Why does the observational part of the study matter less than the randomized part?Because chronic cannabis users and non-users could differ in illness severity or other unmeasured ways, so an association between use and performance is not proof that cannabis caused the difference.Does the acute THC trial settle the question?No

But for others, combining tirzepatide with TRT can provide even greater benefits
Glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor widely expressed on the surface of a wide range of cells in the human body, including pancreatic islet , and cells, as well as multiple tissues such as the intestines, stomach, lungs, heart, kidneys, and central nervous system
There are no significant differences between genders, although some studies based on individual geographic populations suggest a higher prevalence in female subjects (130) and a lower age at diagnosis in male subjects (131)
Glucagon receptor activation This is what makes retatrutide unprecedented